Melperone
Title: Melperone
CAS Registry Number: 3575-80-2
CAS Name: 1-(4-Fluorophenyl)-4-(4-methyl-1-piperidinyl)-1-butanone
Additional Names: 4¢-fluoro-4-(4-methylpiperidino)butyrophenone; g-(4-methylpiperidino)-p-fluorobutyrophenone; methylperone; flubuperone
Molecular Formula: C16H22FNO
Molecular Weight: 263.35
Percent Composition: C 72.97%, H 8.42%, F 7.21%, N 5.32%, O 6.08%
Literature References: Neuroleptic agent related structurally to haloperidol, q.v. Prepn: BE 651144; S. E. H. Hernestam et al., US 3816433 (1964, 1974 both to Ferrosan). Distribution of 14C melperone: N. Einer-Jensen, E. Hansson, Acta Pharmacol. Toxicol. 23, 65 (1965). Pharmacological and toxicological studies: J. A. Christensen et al., ibid. 109; R. Heywood, A. K. Palmer, Farmaco Ed. Prat. 29, 586 (1974). Dopamine-receptor binding in relation to clinical effect: I. Creese et al., Science 192, 481 (1976). Sedative and sleep-inducing properties: R. Kretzschmer et al., Arzneim.-Forsch. 26, 1073 (1976). Clinical studies in anxiety: W. J. Poeldinger, Therapiewoche 30, 4862 (1980); L. F. Fabre, M. J. Napoliello, Curr. Ther. Res. 30, 427 (1981).
Properties: Liquid, bp0.1 120-125°.
Boiling point: bp0.1 120-125°
 
Derivative Type: Hydrochloride
CAS Registry Number: 1622-79-3
Manufacturers' Codes: FG-5111
Trademarks: Buronil (Ferrosan); Eunerpan (Nordmark)
Molecular Formula: C16H22FNO.HCl
Molecular Weight: 299.81
Percent Composition: C 64.10%, H 7.73%, F 6.34%, N 4.67%, O 5.34%, Cl 11.83%
Properties: Crystals, mp 209-211°. LD50 in rats, mice (mg/kg): 330, 230 orally; 40, 35 i.v. (Christensen).
Melting point: mp 209-211°
Toxicity data: LD50 in rats, mice (mg/kg): 330, 230 orally; 40, 35 i.v. (Christensen)
 
Therap-Cat: Antipsychotic.
Keywords: Antipsychotic; Butyrophenones.

Others monographs:
Pseudocumene2,4-Dinitrobenzenesulfenyl ChlorideAntivenin (Latrodectus mactans)Fluorescin
EpicoccononeHydroxypropyl MethylcelluloseBucetinSodium Iodide, Radioactive
FenamidoneLithium BorateVinylidene ChlorideMiraculin
CarbinoxamineOsateroneLead HydroxideSulfur
©2016 DrugLead US FDA&EMEA